<DOC>
	<DOCNO>NCT01821703</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability LY3045697 multiple dos determine long LY3045697 remain body . Each participant expect complete 3 dose period . At least 7 day pass dose period .</brief_summary>
	<brief_title>A Study LY3045697 After Multiple Oral Dosing Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Healthy men woman nonchild bear potential determine medical history physical examination Male participant must agree use medically accept method contraception sexual partner study 90 day end final dosing Female participant must postmenopausal surgically sterile Postmenopausal female participant must age 45 65 year inclusive , must 12 month without menstrual period , 612 month without menstrual period FollicleStimulating Hormone ( FSH ) great ( &gt; ) 40 International Units per Liter ( IU/L ) Male participant surgically sterile female age 18 65 year inclusive Have Body Mass Index ( BMI ) 18.0 32.5 kilogram per square meter ( kg/m2 ) , inclusive , screen Have clinical laboratory test result within normal reference range population investigator site result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sampling Are nonsmokers smoker 5 less cigarettes/cigars/pipes per day determine history Have ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` power drink '' ) , poppy seed tobacco product 48 hour prior entry clinical research facility discharge Are currently enrol , discontinue within last 60 day prior drug administration inclusive , clinical trial involve investigational drug receive regulatory approval indication Have previously complete withdrawn study study investigate study drug Have history presence medical illness include limited cardiovascular , renal , hepatic , respiratory , hematological , endocrine , psychiatric neurological disease , clinically significant laboratory abnormality , judgment investigator , indicate medical problem would preclude study participation Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study , prolong PR QRS interval . In addition , participant follow finding exclude : Confirmed correct QT ( QTcF ) interval &gt; 450 millisecond ( msec ) men &gt; 470 msec woman ; additional ECGs may perform required Complete bundle branch block conduction abnormality mild first degree atrioventricular block Irregular rhythm sinus arrhythmia occasional , rare supraventricular ectopic beat History unexplained syncope Family history unexplained sudden death sudden death due long QT syndrome Twave configuration sufficient quality assess QT interval , determine investigator Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody , hepatitis C and/or positive hepatitis C antibody , hepatitis B and/or positive hepatitis B surface antigen ( HBsAg ) Intend use overthecounter prescription medication within 5 day prior dose , daily multivitamin therapy , stable thyroid hormone replacement medication assess acceptable investigator interfere integrity study data collection . Medications benign indication healthy participant may continue , exception drug may alter adrenal function , blood pressure potassium , use excessive nonsteroidal antiinflammatory drug ( NSAIDs ) , glucocorticoid , diuretic , antihypertensive drug , betaagonists , nasal decongestant Have donate blood 500 milliliter ( mL ) within 60 day prior dose . Donation 1.5 liter blood ( men ) / 1.0 liter blood ( woman ) 10 month precede start study ( first administration study drug ) Have average weekly alcohol intake exceed 21 unit per week participant unwilling stop alcohol within 48 hour entry study discharge period [ 1 unit = 12 ounce ( oz ) 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ] Have abnormal blood pressure ( supine ) define diastolic blood pressure ( DBP ) &gt; 95 less ( &lt; ) 50 millimeter mercury ( mmHg ) and/or systolic blood pressure ( SBP ) &gt; 150 &lt; 90 mmHg confirm least 1 repeat measurement Regularly use know drug abuse show positive finding use urinary drug screening Use natural licorice ( glycyrrhizinic acid ) within 5 day enrollment use study Are unwilling abstain use grapefruitcontaining product saltsubstitutes contain potassium duration study Have know sensitivity unable tolerate spironolactone Have serum potassium &gt; upper limit normal ( result suspect hemolyzed sample may repeat ) Have serum sodium &lt; low limit normal per lab reference range Have serum creatinine &gt; 124 micromole/liter ( μmol/L ) ( male ) ; &gt; 106 μmol/L ( female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>